- Home
- ALVO vs IRON Comparison
ALVO vs IRON Comparison
Compare ALVO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- IRON
- Stock Information
- Founded
- ALVO 2013
- IRON 2017
- Country
- ALVO Luxembourg
- IRON United States
- Employees
- ALVO N/A
- IRON N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- IRON Health Care
- Exchange
- ALVO Nasdaq
- IRON Nasdaq
- Market Cap
- ALVO 2.5B
- IRON 2.0B
- IPO Year
- ALVO N/A
- IRON N/A
- Fundamental
- Price
- ALVO $8.33
- IRON $60.76
- Analyst Decision
- ALVO
- IRON Strong Buy
- Analyst Count
- ALVO 0
- IRON 10
- Target Price
- ALVO N/A
- IRON $97.80
- AVG Volume (30 Days)
- ALVO 486.2K
- IRON 299.1K
- Earning Date
- ALVO 08-13-2025
- IRON 08-07-2025
- Dividend Yield
- ALVO N/A
- IRON N/A
- EPS Growth
- ALVO N/A
- IRON N/A
- EPS
- ALVO 0.22
- IRON N/A
- Revenue
- ALVO $562,478,000.00
- IRON N/A
- Revenue This Year
- ALVO $33.32
- IRON N/A
- Revenue Next Year
- ALVO $46.16
- IRON N/A
- P/E Ratio
- ALVO $37.86
- IRON N/A
- Revenue Growth
- ALVO 82.19
- IRON N/A
- 52 Week Low
- ALVO $7.35
- IRON $30.82
- 52 Week High
- ALVO $13.70
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- ALVO 48.09
- IRON 56.26
- Support Level
- ALVO $7.85
- IRON $59.74
- Resistance Level
- ALVO $8.12
- IRON $63.51
- Average True Range (ATR)
- ALVO 0.27
- IRON 2.05
- MACD
- ALVO 0.01
- IRON -0.00
- Stochastic Oscillator
- ALVO 39.47
- IRON 44.17
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.